Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
646 people get CNDO articles and Market Currents by email alert.
Get email alerts on CNDO »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
GlobeNewswire (May 8, 2013)
-
GlobeNewswire (May 7, 2013)
-
GlobeNewswire (May 6, 2013)
-
GlobeNewswire (May 1, 2013)
-
-
GlobeNewswire (Apr 24, 2013)
-
-
GlobeNewswire (Apr 11, 2013)
-
GlobeNewswire (Apr 3, 2013)
-
GlobeNewswire (Mar 14, 2013)
-
GlobeNewswire (Mar 11, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
-
GlobeNewswire (Feb 27, 2013)
-
GlobeNewswire (Feb 25, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
Weekly Stock Watch: April 9-13VFC's Stock House • Mon, Apr 9, 2012 -
-
GlobeNewswire (May 8, 2013)
-
GlobeNewswire (May 7, 2013)
-
GlobeNewswire (May 6, 2013)
-
GlobeNewswire (May 1, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
GlobeNewswire (Apr 11, 2013)
-
GlobeNewswire (Apr 3, 2013)
-
GlobeNewswire (Mar 14, 2013)
-
GlobeNewswire (Mar 11, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
GlobeNewswire (Feb 27, 2013)
-
GlobeNewswire (Feb 25, 2013)
-
GlobeNewswire (Feb 19, 2013)
-
GlobeNewswire (Feb 7, 2013)
-
GlobeNewswire (Jan 2, 2013)
-
GlobeNewswire (Dec 27, 2012)
-
GlobeNewswire (Dec 21, 2012)
-
GlobeNewswire (Dec 5, 2012)
-
GlobeNewswire (Nov 28, 2012)
CNDO vs. ETF Alternatives
Company Description
Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The Company's two principal pharmaceutical product candidates in clinical development are: CNDO-201, a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and... More
Country: United States
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 8, 7:28 AM Coronado Biosciences (CNDO): Q1 EPS of -$0.35 misses by $0.05. (PR) Comment! [Earnings, Breaking News]
- Monday, April 22, 9:44 AM Coronado Biosciences (CNDO +7.6%) gets a lift from a Bank of America initiation (Buy). Analyst Steve Byrne calls the company's approach to treating autoimmune diseases (the use of an commensal intestinal parasite) "compelling." While the adoption of the company's products "could be slow, the potential is enormous," Byrne continues. Price target: $17. (See also: Canaccord encouraged by CNDO trials) 1 Comment [Healthcare, On the Move]
- Thursday, April 11, 3:45 PM Coronado Biosciences (CNDO +10.6%) moves up after raising $9.9M and $7.6M (after expenses) in at-the-market offerings managed by MLV & Co. The company says it will either fund R&D or will invest the proceeds in short-term marketable securities. Prior to the offering, the company had raised $10.5M YTD under the ATM program. (See earnings transcript) Comment! [Healthcare, On the Move]
- Monday, March 25, 11:08 AM Coronado Biosciences (CNDO +4.1%) moves up today after Canaccord initated coverage with a Buy rating and an $18 price target. Canaccord says it's ecouraged by Phase 2 trials for Trichuris suis ova, a biologic composed of pig whipworm eggs being tested for the treatment of Crohn's disease. The firm notes that the drug has a novel mechanism, and physician feedback indicates a high likelihood of success for the upcoming data, which could be an important catalyst for the stock in H2. Comment! [Healthcare, On the Move]
- Thursday, March 14, 7:24 AM Coronado Biosciences (CNDO): Q4 EPS of -$0.36 misses by $0.09. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, January 22, 12:03 PM Coronado Biosciences (CNDO +4.1%) gets a pop after Roth Capital adds it to its Focus List and calls it a top 2013 Biotech pick. The firm cites optimism over its lead product TSO and its potential for treating Crohn's disease, and assigns a whopping price target of $24 on the shares, representing a +350% premiuim to its current price. 2 Comments [Healthcare, On the Move]
- Wednesday, January 2, 11:35 AM Coronado Biosciences (CNDO +6.2%) gets a pop after naming Harlan F. Weisman, M.D., as its new chairman and CEO. Dr. Weisman has been a director for the company since August 2012. Comment! [Healthcare, On the Move]
- Friday, December 21, 2012, 1:47 PM Coronado Biosciences (CNDO -5.9%) says it's signed a clinical trial agreement with the National Institute of Allergy and Infectious Diseases to evaluate its experimental Trichuris suis ova, or CNDO-201, for the treatment of ulcerative colitis. The multi-center study will examine the safety and efficacy of TSO treatment in active left-sided ulcerative colitis and its effects on mucosal immune state and microbiota. Comment! [Healthcare, On the Move]
- Wednesday, November 14, 2012, 7:36 AM Coronado Biosciences (CNDO): Q3 EPS of -$0.24 beats by $0.04. (PR) Comment! [Earnings, Healthcare]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.